An analysis of the clinical utility of the Hematotox-Score demonstrated the tool is predictive of hematologic toxicity in patients undergoing CAR-T therapy, but is not predictive of mortality.
More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation therapy, according to researchers.
The objective response rate was 70.0% in the HER3-DXd arm and 70.8% in the chemotherapy arm. Patritumab deruxtecan (HER3-DXd), given with or without letrozole, produced similar outcomes as multi ...
There is no indication that Luigi Mangione, the man charged with killing UnitedHealthcare CEO Brian Thompson, was ever a client of UnitedHealthcare, according to authorities.